Form 8-K Cullinan Therapeutics, For: Sep 17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BTIG Reiterates Buy Rating on Cullinan Oncology Inc. (CGEM)
September 18, 2024 6:20 AM EDTBTIG analyst Julian Harrison reiterated a Buy rating and $30.00 price target on Cullinan Oncology Inc. (NASDAQ: CGEM).
The analyst comments "Mgmt. has received regulatory approval to initiate the global Phase 1 trial for SLE in Australia. In the US, we expect the IND to open in ~30 days, assuming no further inquiries from the... More
